Home > Gastroenterology > UEGW 2021 > Updates in Small Molecules > First pharmacological therapy with clear efficacy in coeliac disease patients

First pharmacological therapy with clear efficacy in coeliac disease patients

Presented by
Prof. Detlef Schuppan, Mainz University Medical Center, Germany
Conference
UEGW 2021
Trial
Phase 2
The administration of ZED-1227 demonstrated clinical and histological efficacy in patients with coeliac disease. This is the first pharmacological therapy for coeliac disease patients that showed efficacy in a phase 2a trial. Moreover, no important side effects were reported. A phase 2b/3 trial will be conducted among symptomatic coeliac disease patients at the end of this year to investigate the full potential of the new agent.

A gluten-free diet is the most important therapy for coeliac disease patients. Beyond the psychological and social burden of maintaining a strict gluten-free diet, minimal gluten intake cannot be avoided. Minimal ingestion of gluten can already cause symptoms in 30% of the patients, according to Prof. Detlef Schuppan (Mainz University Medical Center, Germany). Therefore, a supportive pharmacological therapy is needed. Currently there is no effective or approved drug for coeliac disease. A phase 2a trial examined ZED-1227, an irreversible transglutaminase-2 inhibitor, among 160 coeliac patients in remission who followed a gluten-free diet [1]. All patients were to eat a standardised cookie with 3 g gluten daily for 6 weeks and were randomised to 10 mg, 50 mg, or 100 mg of ZED-1227 (oral, once daily), or placebo. Primary endpoint was histological damage, represented by villus height to crypt depth ratio.

Patients in all ZED-1227 conditions showed significantly improved villus height to crypt depth ratios compared with patients receiving placebo (P<0.001). Similarly, the intraepithelial lymphocyte (IEL) density was significantly lower in the ZED-1227 groups, compared with placebo. Other secondary endpoints, such as the Celiac Disease Questionnaire Gastrointestinal (CDQ GI) symptom subscore, transglutaminase-2 autoantibodies, and markers of inflammation showed patient benefits for the ZED-1227 subjects. To conclude, no relevant side effects were reported in this trial.

  1. Schuppan D, et al. Oral inhibitor of transglutaminase 2 prevents mucosal damage in coeliac patients undergoing gluten challenge. LB06, UEG Week 2021 Virtual Congress, 03–05 October.

 

Copyright ©2021 Medicom Medical Publishers



Posted on